Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.
Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia.
Rosse
R B
RB
Psychiatry Service, Department of Veterans Affairs Medical Center, Washington, D.C. 20422, USA.
Kendrick
K
K
Tsui
L C
LC
Fay-McCarthy
M
M
Collins
J P
JP
Rosenberg
P
P
Wyatt
R J
RJ
Deutsch
S I
SI
D015738:Famotidine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008972:Molindone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*
D015738:Famotidine; D008972:Molindone